Here are what the editors at HealthDay consider to be the most important developments in OBGYN & Women’s Health for February 2019. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Flu Vaccination During Pregnancy Does Not Cause Miscarriage
THURSDAY, Feb. 28, 2019 (HealthDay News) — An influenza vaccine cannot cause a pregnant woman to miscarry, researchers say.
Robotically Assisted Devices Not Approved for Cancer Surgery
THURSDAY, Feb. 28, 2019 (HealthDay News) — The use of robotically assisted surgical devices for breast removal and other cancer-related surgeries is not approved by the U.S. Food and Drug Administration because there is no proof of its safety or effectiveness in such cases, the agency says in a warning to doctors and patients.
Performance Improvement Sustained After DBT Adoption
THURSDAY, Feb. 28, 2019 (HealthDay News) — Performance improvements after adoption of digital breast tomosynthesis (DBT) relative to digital mammography (DM) performance have been sustained, regardless of DBT volume, according to a study published online Feb. 26 in Radiology.
CDC: Progress in HIV Prevention Has Stalled in the United States
WEDNESDAY, Feb. 27, 2019 (HealthDay News) — The battle against new HIV infections has lost some steam in recent years, according to the U.S. Centers for Disease Control and Prevention.
Prenatal Vitamin Intake in Early Pregnancy May Cut Autism Risk
WEDNESDAY, Feb. 27, 2019 (HealthDay News) — Maternal prenatal vitamin intake during the first month of pregnancy is associated with a reduced risk for autism spectrum disorder (ASD) in siblings of children with ASD, according to a study published online Feb. 27 in JAMA Psychiatry.
Lymphadenectomy Does Not Up Survival in Advanced Ovarian Cancer
WEDNESDAY, Feb. 27, 2019 (HealthDay News) — For patients with advanced ovarian cancer who have undergone intra-abdominal macroscopically complete resection and have clinically negative lymph nodes, lymphadenectomy is not associated with longer overall or progression-free survival, according to a study published in the Feb. 28 issue of the New England Journal of Medicine.
Decline Observed in HPV Type 16/18 Cervical Precancers in U.S.
WEDNESDAY, Feb. 27, 2019 (HealthDay News) — The proportion of human papillomavirus (HPV) 16/18-positive cervical intraepithelial neoplasia grades 2 to 3 or adenocarcinoma in situ (CIN2+) declined from 2008 to 2014, according to a study published online Feb. 21 in Cancer Epidemiology, Biomarkers & Prevention.